At Adelaide University, researchers have cracked a problem that has plagued cancer medicine for decades: how to deliver drugs precisely where they're needed while leaving healthy tissue untouched. Their solution is a microscopic one—hybrid nanoparticles made from lipids and polymers that act as delivery vehicles, boosting the effectiveness of lung cancer drugs by more than 30-fold.
Lung cancer remains one of the world's deadliest cancers, yet many promising drugs fail in treatment because they don't linger long enough in the body to work, or worse, they damage healthy organs on the way. The real culprit is the liver, the body's natural filtering system, which intercepts most drugs before they can reach their intended target. "One of the major challenges in treating lung cancer is that many drugs don't stay in the body long enough, or they spread to healthy organs and cause toxic side effects," explained Senior Research Fellow Dr. Paul Joyce. "Normally, much of a drug ends up in the liver instead of reaching the lungs."
The Adelaide team's breakthrough encapsulates a promising lung cancer drug called RB-012 within nanoparticles composed of materials already used safely in existing medicines. These particles act like a protective vessel, allowing the drug to circulate longer while directing it specifically to lung tumors. In preclinical testing, the nanoparticle-delivered drug showed stronger tumor-killing effects compared to the drug administered on its own—a finding Dr. Joyce illustrates with a vivid metaphor: administering a standard cancer drug is like "pouring water into a leaky bucket," whereas their nanoparticle approach "seals that bucket so that 30 times more water stays inside."
The research, published in the Journal of Controlled Release, emerged from laboratory experiments and preclinical models in which the team meticulously tracked how long the drug stayed in the bloodstream, where it traveled in the body, and how effectively it reached lung tumors. The results suggest that by improving drug delivery, clinicians could potentially increase treatment effectiveness while simultaneously reducing harm to healthy tissue—a dual benefit that could reshape how lung cancer patients are treated.
What makes this work particularly significant is its potential ripple effect. While the current focus is lung cancer, the delivery system's principles could extend far beyond. Any disease where targeted drug delivery is critical could potentially benefit from this approach, opening doors to a new generation of precision medicines. The team at Adelaide University is already planning the next phase: testing the nanoparticles in more advanced preclinical models to confirm safety and effectiveness before moving toward human clinical trials.
The journey from laboratory discovery to patient treatment is long and uncertain, but early signs are encouraging. Dr. Joyce frames the work as fundamentally about fairness to patients and to science itself: "This is about giving promising drugs the best chance to work." For people with lung cancer, a disease that claims over a million lives annually worldwide, that best chance could make all the difference.